Rising Tide Lifts All CAR-T Ships After Gilead/Kite Deal, Kymriah Approval
Executive Summary
Excitement around cell therapy has been building in recent years, but companies expect interest to accelerate after Gilead agreed to buy Kite for $11.9bn and Novartis won the first ever CAR-T approval.
You may also be interested in...
ASH 2020: J&J/Legend’s Cilta-Cel Shines, But BMS/Bluebird’s Ide-Cel Is In First Place
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Finance Watch: In Obesity, Vivus Raises Cash For Deals, Orexigen Finds A Buyer
Public Company Edition: Strategies diverge in obesity as Vivus restructures debt and raises cash for a new deal and new focus, after Orexigen nears a sale of the company via bankruptcy court. Also, Clovis leads recent offerings, while layoffs are on the table at Catabasis.
TCR2 Raises $125m To Make T-Cell Therapies Available To More Cancer Patients
TCR2 Therapeutics raised a $125m Series B round to take two T-cell receptor (TCR)-based therapies into the clinic for solid tumors. The company's technology platform overcomes HLA-matching issues to make TCR-based treatments available to more patients.